Exane Derivatives’s Emerson Electric EMR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
$312K Sell
3,921
-2,022
-34% -$178K 0.18% 130
2022
Q1
$583K Hold
5,943
0.16% 170
2021
Q4
$553K Buy
5,943
+919
+18% +$86.5K 0.13% 161
2021
Q3
$473K Buy
5,024
+222
+5% +$22.1K 0.11% 198
2021
Q2
$470K Buy
4,802
+2,235
+87% +$210K 0.11% 194
2021
Q1
$232K Sell
2,567
-210
-8% -$18.1K 0.07% 279
2020
Q4
$223K Sell
2,777
-15,265
-85% -$1.13M 0.07% 295
2020
Q3
$1.18M Sell
18,042
-18,042
-50% -$1.19M 0.34% 63
2020
Q2
$2.24M Buy
36,084
+36,035
+73,541% +$2.05M 0.6% 43
2020
Q1
$2.33K Hold
49
﹤0.01% 489
2019
Q4
$3.75K Hold
49
﹤0.01% 456
2019
Q3
$3.28K Sell
49
-888
-95% -$55.8K ﹤0.01% 464
2019
Q2
$62.5K Sell
937
-54,099
-98% -$3.62M 0.01% 370
2019
Q1
$3.77M Buy
55,036
+54,860
+31,170% +$3.61M 0.74% 40
2018
Q4
$10.5K Hold
176
﹤0.01% 460
2018
Q3
$13.5K Buy
176
+164
+1,367% +$12.1K ﹤0.01% 432
2018
Q2
$837 Buy
+12
New +$843 ﹤0.01% 539

Other funds holding EMR

Exane Derivatives's EMR Position: Q2 2022 in Review

Exane Derivatives reduced its Emerson Electric (EMR) stake by 34% in Q2 2022, selling an estimated $178K and leaving 3,921 shares worth $312K. The position accounts for 0.18% of the portfolio, ranked #130.

Exane Derivatives first reported a position in EMR in Q2 2018 and has held it in 17 quarters since. The position peaked at $3.77M in Q1 2019. 1,722 funds tracked by Wall St. Rank hold EMR as of Q2 2022.

  • Exane Derivatives held 3,921 shares of Emerson Electric worth $312K as of Q2 2022.
  • Exane Derivatives sold 2,022 Emerson Electric shares in Q2 2022, an estimated $178K.
  • Emerson Electric made up 0.18% of Exane Derivatives's portfolio in Q2 2022, its #130 holding.
  • Exane Derivatives first reported a position in Emerson Electric in Q2 2018 and has held it in 17 quarters since.
  • Exane Derivatives's Emerson Electric position peaked at $3.77M in Q1 2019.
  • 1,722 funds tracked by Wall St. Rank held Emerson Electric as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.